Aptuit

Aptuit, Inc. has appointed Dr. Michael J. Butler president, scientific operations of its drug development services. He will assume responsibility for all of Aptuit’s scientific operations, which span API development, preclinical technologies, analytics, and pharmaceutics, consisting of more than 875 scientists and technical staff in Kansas City, MO and Edinburgh, Scotland.

Dr. Butler has 20 years of experience in pharmaceutical drug development. He most recently served as group vice president, early clinical and bioanalytical, and senior vice president, marketing and business development at MDS Pharma Services, where he led multi-site operations and oversaw strategic alignment of the company’s global operations.

Prior to MDS, Dr. Butler was the former group director, business development and director, pharmaceutical business development for Huntingdon Life Sciences. He was also the director, customer service at Lockheed Environmental Systems and Technology Co. and head of department, Corning Enseco, Inc.